AbbVie Inc. (ABBV) Stock Price Today — Live Chart and Analysis

The company’s stock has under-performed the broader market so far in 2025, while the company managed to beat EPS consensus estimates during the last quarter results. Meanwhile, the company’s number one drug Humira is further gaining approval for several indications and as a result, it will continue to contribute significantly in revenue growth for the company. Moreover, past acquisitions are now getting ripe to contribute in revenue growth while the company’s strong pipeline includes many late stage candidates for approval by FDA, which increases the probabilities for future growth, assuming some of the drugs will be approved. On the downside, the company currently relies heavily in the success of Humira while another company drug Viekira has not performed as expected. Going forward, the company is facing strong competition from bio-similar products and intense competition from industry giants like Johnson and Johnson. In addition, any delays in FDA approvals could have a negative impact on the company’s future financial performance.